Shilpa Medicare
Market Cap
₹22.0b
Last Updated
2019/10/16 12:38 UTC
Data Sources
Company Financials +
Executive Summary
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells generic active pharmaceutical ingredients (APIs) and formulations in India, the United States, Europe, and internationally..
Snowflake
Fundamentals
Flawless balance sheet with reasonable growth potential and pays a dividend.
Similar Companies
Share Price & News
How has Shilpa Medicare's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-2.3%
530549
1.4%
IN Pharmaceuticals
1.4%
IN Market
1 Year Return
-34.4%
530549
-20.0%
IN Pharmaceuticals
2.3%
IN Market
Return vs Industry: 530549 underperformed the Indian Pharmaceuticals industry which returned -20% over the past year.
Return vs Market: 530549 underperformed the Indian Market which returned 2.3% over the past year.
Shareholder returns
| 530549 | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.3% | 1.4% | 1.4% |
| 30 Day | -2.1% | -7.1% | 2.7% |
| 90 Day | -27.5% | -5.2% | -1.4% |
| 1 Year | -34.1%-34.4% | -19.3%-20.0% | 4.3%2.3% |
| 3 Year | -56.4%-56.7% | -27.3%-28.8% | 20.9%14.9% |
| 5 Year | -2.5%-3.4% | -11.9%-14.6% | 41.2%28.2% |
Price Volatility Vs. Market
How volatile is Shilpa Medicare's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall St
Will Shilpa Medicare Limited (BOM:530549) Continue To Underperform Its Industry?1 year ago | Simply Wall St
Top BSE Growth Stocks To Buy1 year ago | Simply Wall St
Top BSE Growth Stocks To BuyValuation
Is Shilpa Medicare undervalued compared to its fair value and its price relative to the market?
22.22x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Undervalued: 530549 (₹257.05) is trading above our estimate of fair value (₹13.08)
Significantly Undervalued: 530549 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 530549 is poor value based on its PE Ratio (22.2x) compared to the Pharmaceuticals industry average (15.6x).
PE vs Market: 530549 is poor value based on its PE Ratio (22.2x) compared to the Indian market (13x).
Price to Earnings Growth Ratio
Low PEG Ratio: 530549 is good value based on its PEG Ratio (1x)
Price to Book Ratio
PB vs Industry: 530549 is overvalued based on its PB Ratio (1.7x) compared to the IN Pharmaceuticals industry average (1.5x).
Next Steps
Future Growth
How is Shilpa Medicare forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
23.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 530549's forecast earnings growth (23.1% per year) is above the savings rate (7.6%).
Earnings vs Market: 530549's earnings (23.1% per year) are forecast to grow faster than the Indian market (18.1% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 530549's revenue (15.4% per year) is forecast to grow faster than the Indian market (11.4% per year).
High Growth Revenue: 530549's revenue (15.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: 530549's Return on Equity is forecast to be low in 3 years time (11.4%).
Next Steps
Past Performance
How has Shilpa Medicare performed over the past 5 years?
9.0%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: 530549's earnings have grown by 9% per year over the past 5 years.
Accelerating Growth: 530549's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 530549 had negative earnings growth (-19.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (14.4%).
Return on Equity
High ROE: 530549's Return on Equity (7.7%) is considered low.
Return on Assets
ROA vs Industry: 530549's Return on Assets is below or equal to the Pharmaceuticals industry average last year.
Return on Capital Employed
ROCE Improving: 530549's Return on Capital Employed has declined over the past 3 years.
Next Steps
Financial Health
How is Shilpa Medicare's financial position?
Financial Position Analysis
Short Term Liabilities: 530549's short term assets (₹5.5B) exceeds its short term liabilities (₹2.5B)
Long Term Liabilities: 530549's short term assets (5.5B) exceeds its long term liabilities (1.7B)
Debt to Equity History and Analysis
Debt Level: 530549's debt to equity ratio (14.1%) is considered satisfactory
Reducing Debt: 530549's debt to equity ratio has reduced from 24.2% to 14.1% over the past 5 years.
Debt Coverage: 530549's debt is well covered by operating cash flow (82.8%).
Interest Coverage: 530549's interest payments on its debt are well covered by EBIT (19.2x coverage).
Balance Sheet
Inventory Level: 530549 has a high level of physical assets or inventory.
Debt Coverage by Assets: 530549's debt is covered by short term assets (assets are 3.251270x debt).
Next Steps
Dividend
What is Shilpa Medicare's current dividend yield, its reliability and sustainability?
0.39%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: 530549's dividend (0.39%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.61%).
High Dividend: 530549's dividend (0.39%) is low compared to the top 25% of dividend payers in the Indian market (2.51%).
Stable Dividend: 530549's dividends per share have been stable in the past 10 years.
Growing Dividend: 530549's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (8.6%), 530549's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 530549's dividends in 3 years are forecast to be thoroughly covered by earnings (4.7% payout ratio).
Next Steps
Management
What is the CEO of Shilpa Medicare's salary, the management and board of directors tenure and is there insider trading?
6.2yrs
Average board tenure
CEO
Vishnukanth Bhutada (57yo)
0yrs
Tenure
₹74,737,000
Compensation
Mr. Vishnukanth Chaturbhuj Bhutada, B. Pharm. serves as the Managing Director of Shilpa Medicare Limited. Mr. Bhutada joined Shilpa Medicare Limited in November 1987. He serves as the Director at Maia Phar ...
CEO Compensation Analysis
Compensation vs. Market: Vishnukanth's total compensation ($USD1.05M) is above average for companies of similar size in the Indian market ($USD324.68K).
Compensation vs Earnings: Vishnukanth's compensation has been consistent with company performance over the past year.
Board Age and Tenure
6.2yrs
Average Tenure
51yo
Average Age
Experienced Board: 530549's board of directors are considered experienced (6.2 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Management Team
Vinay Konaje (46yo)
Business Head of Biologics
- Tenure: 0yrs
Vishnukanth Bhutada (57yo)
MD & Director
- Tenure: 0yrs
- Compensation: ₹74.74m
Rajkumar Somani (52yo)
Vice President
- Tenure: 0yrs
Janak Kastia (58yo)
CEO - US Formulations and GM of Marketing & Business Development - USA & Global Generic Cos
- Tenure: 0yrs
- Compensation: ₹9.56m
Pramod Kumar (56yo)
Senior Vice President of Technical
- Tenure: 0yrs
- Compensation: ₹6.06m
Sharath Kalakota (52yo)
VP of Technical & Whole-time Director
- Tenure: 0yrs
Sushil Bajaj
CFO & Compliance Officer
- Tenure: 1.9yrs
- Compensation: ₹4.09m
Rajyashri Ramakrishnan (55yo)
Chief Scientific Officer of Biologicals
- Tenure: 0yrs
V.V. Chaitanya
Company Secretary
- Tenure: 0yrs
Board Members
Amit Chander (40yo)
Independent Director
- Tenure: 0.5yrs
Pramod Kasat (50yo)
Independent Director
- Tenure: 9.6yrs
- Compensation: ₹20.00k
Om Inani (63yo)
Non-Executive Chairman
- Tenure: 0yrs
- Compensation: ₹20.00k
Vishnukanth Bhutada (57yo)
MD & Director
- Tenure: 0yrs
- Compensation: ₹74.74m
Rajender Reddy (55yo)
Independent Director
- Tenure: 11.3yrs
- Compensation: ₹20.00k
Naresh Patwari (41yo)
Non-Executive Director
- Tenure: 2.8yrs
Sharath Kalakota (52yo)
VP of Technical & Whole-time Director
- Tenure: 0yrs
Sirisha Chintapalli (39yo)
Independent Director
- Tenure: 0.5yrs
Company Information
Shilpa Medicare Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Shilpa Medicare Limited
- Ticker: 530549
- Exchange: BSE
- Founded: 1987
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹21.971b
- Shares outstanding: 81.53m
- Website: https://www.vbshilpa.com
Location
- Shilpa Medicare Limited
- Shilpa House
- #12-6-214/A1
- Raichur
- Karnataka
- 584135
- India
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 530549 | BSE (Mumbai Stock Exchange) | Yes | Equity Shares | IN | INR | Jul 1995 |
| SHILPAMED | NSEI (National Stock Exchange of India) | Yes | Equity Shares | IN | INR | Jul 1995 |
| 530549 | BSE (Mumbai Stock Exchange) | INR1 | IN | INR | Nov 2015 | |
| SHILPAMED | NSEI (National Stock Exchange of India) | INR1 | IN | INR | Nov 2015 |
Biography
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells generic active pharmaceutical ingredients (APIs) and formulations in India, the United States, Europe, and internationally.. ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/16 12:38 |
| End of Day Share Price | 2019/10/16 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2019/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.